Nuvation Bio Publishes Corporate Presentation on IBTROZI ROS1 Lung Cancer and Safusidenib IDH1 Glioma Pipeline

Reuters03-03 05:22

<a href="https://laohu8.com/S/NUVB">Nuvation Bio</a> Publishes Corporate Presentation on IBTROZI ROS1 Lung Cancer and Safusidenib IDH1 Glioma Pipeline

Nuvation Bio Inc. highlighted its oncology portfolio, including IBTROZI (taletrectinib), a ROS1 inhibitor approved in the U.S., Japan and China for advanced ROS1-positive non-small cell lung cancer. The company reported 2025 U.S. net product revenue of $24.7 million and 432 new patient starts since launch, and said it is enrolling the TRUST-IV study in early-stage ROS1-positive NSCLC. The presentation also outlined development of safusidenib, an IDH1 inhibitor being evaluated in the pivotal SIGMA study for high-risk or high-grade IDH1-mutant astrocytoma, alongside a non-pivotal cohort for grade 3 IDH1-mutant oligodendroglioma. Nuvation Bio also described ongoing evaluation of preclinical candidates from its Drug-Drug Conjugate platform and reported a pro forma cash balance of approximately $589 million. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on March 02, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616436913?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 05:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616436913","market":"us","top_or_hot":-1,"title":"Nuvation Bio Publishes Corporate Presentation on IBTROZI ROS1 Lung Cancer and Safusidenib IDH1 Glioma Pipeline","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a> Publishes Corporate Presentation on IBTROZI ROS1 Lung Cancer and Safusidenib IDH1 Glioma Pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NUVB.WS\">Nuvation Bio</a> Inc. highlighted its oncology portfolio, including IBTROZI (taletrectinib), a ROS1 inhibitor approved in the U.S., Japan and China for advanced ROS1-positive non-small cell lung cancer. The company reported 2025 U.S. net product revenue of $24.7 million and 432 new patient starts since launch, and said it is enrolling the TRUST-IV study in early-stage ROS1-positive NSCLC. The presentation also outlined development of safusidenib, an IDH1 inhibitor being evaluated in the pivotal SIGMA study for high-risk or high-grade IDH1-mutant astrocytoma, alongside a non-pivotal cohort for grade 3 IDH1-mutant oligodendroglioma. Nuvation Bio also described ongoing evaluation of preclinical candidates from its Drug-Drug Conjugate platform and reported a pro forma cash balance of approximately $589 million. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on March 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvation Bio Publishes Corporate Presentation on IBTROZI ROS1 Lung Cancer and Safusidenib IDH1 Glioma Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvation Bio Publishes Corporate Presentation on IBTROZI ROS1 Lung Cancer and Safusidenib IDH1 Glioma Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-03 05:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a> Publishes Corporate Presentation on IBTROZI ROS1 Lung Cancer and Safusidenib IDH1 Glioma Pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NUVB.WS\">Nuvation Bio</a> Inc. highlighted its oncology portfolio, including IBTROZI (taletrectinib), a ROS1 inhibitor approved in the U.S., Japan and China for advanced ROS1-positive non-small cell lung cancer. The company reported 2025 U.S. net product revenue of $24.7 million and 432 new patient starts since launch, and said it is enrolling the TRUST-IV study in early-stage ROS1-positive NSCLC. The presentation also outlined development of safusidenib, an IDH1 inhibitor being evaluated in the pivotal SIGMA study for high-risk or high-grade IDH1-mutant astrocytoma, alongside a non-pivotal cohort for grade 3 IDH1-mutant oligodendroglioma. Nuvation Bio also described ongoing evaluation of preclinical candidates from its Drug-Drug Conjugate platform and reported a pro forma cash balance of approximately $589 million. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on March 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NUVB","symbol_name":"Nuvation Bio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL5ZlwK6:1","article_id":"2616436913","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616436913","pubTimestamp":1772486547,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nuvation Bio Inc. highlighted its oncology portfolio, including IBTROZI , a ROS1 inhibitor approved in the U.S., Japan and China for advanced ROS1-positive non-small cell lung cancer. The company reported 2025 U.S. net product revenue of $24.7 million and 432 new patient starts since launch, and said it is enrolling the TRUST-IV study in early-stage ROS1-positive NSCLC. The presentation also outlined development of safusidenib, an IDH1 inhibitor being evaluated in the pivotal SIGMA study for high-risk or high-grade IDH1-mutant astrocytoma, alongside a non-pivotal cohort for grade 3 IDH1-mutant oligodendroglioma. Nuvation Bio also described ongoing evaluation of preclinical candidates from its Drug-Drug Conjugate platform and reported a pro forma cash balance of approximately $589 million. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NUVB":"Nuvation Bio, Inc.","BK4007":"制药"},"translate_title":"Nuvation Bio发布关于IBTROZI ROS1肺癌和Safusidenib IDH1神经胶质瘤管线的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NUVB":0.9},"content_text":"Nuvation Bio Publishes Corporate Presentation on IBTROZI ROS1 Lung Cancer and Safusidenib IDH1 Glioma Pipeline\n    \n\nNuvation Bio Inc. highlighted its oncology portfolio, including IBTROZI (taletrectinib), a ROS1 inhibitor approved in the U.S., Japan and China for advanced ROS1-positive non-small cell lung cancer. The company reported 2025 U.S. net product revenue of $24.7 million and 432 new patient starts since launch, and said it is enrolling the TRUST-IV study in early-stage ROS1-positive NSCLC. The presentation also outlined development of safusidenib, an IDH1 inhibitor being evaluated in the pivotal SIGMA study for high-risk or high-grade IDH1-mutant astrocytoma, alongside a non-pivotal cohort for grade 3 IDH1-mutant oligodendroglioma. Nuvation Bio also described ongoing evaluation of preclinical candidates from its Drug-Drug Conjugate platform and reported a pro forma cash balance of approximately $589 million. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on March 02, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616436913","isCrawlerRequest":true}